Fletchy - you won't see "every company" following IHL down this path. Will not happen. It is extremely hard to find people of Paul Liknaitzky's calibre with the skills, experience, connections and peer respect to develop projects of significance in this space. IHL has also proven its abilities in the clinical pathway arena adopting the highest standards and abilities to develop and innovate.
What investors may miss is that while psychedelics may feel "new" to some investors, it has been developing in a very respected and sophisticated framework with some very serious players. Relationships, credibility and skills are paramount with potential partnering hospitals, institutes, etc.... good reasons why only a few are at the necessary standard IMO.
